Meeting
2022 ASCO Annual Meeting
Association of germline genetic testing results with chemotherapy regimens received by women with early-stage breast cancer.
Authors
Allison W. Kurian
Stanford University School of Medicine, Stanford, CA
Allison W. Kurian , Paul Abrahamse , Jennifer Lee Caswell-Jin , Ann S. Hamilton , Timothy Hofer , Kevin C Ward , Steven Katz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Hereditary Cancer Syndromes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10518)
DOI
10.1200/JCO.2022.40.16_suppl.10518
Abstract #
10518
Poster Bd #
397
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Improving access to cancer genetic testing for underserved women in southeast Texas.
First Author: Darya Aleksandrovna Kizub
Poster
2017 Genitourinary Cancers Symposium
Inherited pathologic mutations and family history in patients with prostate cancer.
First Author: Shuwen Lin
Poster
2024 ASCO Annual Meeting
Variant of uncertain significance (VUS) genetic testing results and mastectomy choice in lumpectomy-eligible patients.
First Author: Osvaldo Nunez Jr. Jr.
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Incidence and prognostic value of actionable mutations in early-stage resectable cholangiocarcinoma.
First Author: Kailey Morgan Oppat